Site
Search results
Janssen Receives Positive CHMP Opinion for Spravato® (esketamine) Nasal Spray for Adults with Treatment-Resistant Major Depressive Disorder
Oct 18, 2019 Belgium If approved by the European Commission, esketamine nasal spray will offer the first new mechanism of action in 30 years to treat major depressive disorder (MDD) In the phase III clinical development programme with flexible dosing, ...
New Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Sep 09, 2019 United States Global clinical program is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies TITUSVILLE, NJ, SEPTEMBER 9, 2019 – The Janssen Pharmaceutical Companies of ...
SPRAVATO®▼ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder
Dec 19, 2019 Belgium Esketamine nasal spray offers the first new mechanism of action for an antidepressant in 30 years EC approval is based on data from a clinical trial programme in adult patients with treatment-resistant major depressive disorder, ...
FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
Feb 12, 2019 United States If approved, SPRAVATO™ will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen's 60-plus-year history and commitment to research that make a difference for people ...
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Oct 02, 2019 United States If approved, SPRAVATO ® would be the first treatment for this severely ill population 1 who historically have been excluded from antidepressant clinical trials Submission is based on data from the ASPIRE I & II trials ...
New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
May 21, 2019 United States NEW ORLEANS, May 21, 2019 -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented a new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting ...
Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
Jan 15, 2020 Belgium In two pivotal Phase 3 trials, SPRAVATO ® ▼ combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms in patients with major depressive disorder who have current suicidal ...
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
Aug 03, 2020 United States- SPRAVATO® is the first and only approved antidepressant medication shown to begin improving depressive symptoms with the first dose in this challenging to treat patient population- Approval is based on Phase 3 data showing ...
Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
Mar 05, 2019 United States SPRAVATO™ uses the first new mechanism of action in decades to treat major depressive disorder 1,2,3 In short- and long-term clinical trials, those who received SPRAVATO™ and a newly initiated oral antidepressant achieved ...
The MSVirtual 2020 Newsroom
OUR Commitment to Multiple Sclerosis Thank you for visiting the Janssen Neuroscience R&D MSVirtual2020 Newsroom! Below, please find our meeting news, social feeds, and more information about our progress and commitment to developing innovative ...